CEO Rodolphe Clerval describes the platform, which they can partner using a company's existing AAV assets or with Coave's new OneAAV universal capsid. Plus, why he thinks Coave's wet AMD program, which will be administered at the point of care, could be best in class. Coverage brought to you by

CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered...

CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector...